Cargando…
Cell-Specific Protective Signaling Induced by the Novel AT2R-Agonist NP-6A4 on Human Endothelial and Smooth Muscle Cells
Cardiovascular disease incidence continues to rise and new treatment paradigms are warranted. We reported previously that activation of Angiotensin II receptor (encoded by the X-linked Agtr2 gene) by a new peptide agonist, NP-6A4, was more effective in protecting mouse cardiomyocyte HL-1 cells and h...
Autores principales: | Toedebusch, Ryan, Belenchia, Anthony, Pulakat, Lakshmi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111462/ https://www.ncbi.nlm.nih.gov/pubmed/30186168 http://dx.doi.org/10.3389/fphar.2018.00928 |
Ejemplares similares
-
AT2R agonist NP‐6A4 mitigates aortic stiffness and proteolytic activity in mouse model of aneurysm
por: Sharma, Neekun, et al.
Publicado: (2020) -
Suppression of Inflammatory Cardiac Cytokine Network in Rats with Untreated Obesity and Pre-Diabetes by AT2 Receptor Agonist NP-6A4
por: Gavini, Madhavi P., et al.
Publicado: (2021) -
Diabetic Cardiomyopathy: Impact of Biological Sex on Disease Development and Molecular Signatures
por: Toedebusch, Ryan, et al.
Publicado: (2018) -
Differential Effects of β-Blockers, Angiotensin II Receptor Blockers, and a Novel AT2R Agonist NP-6A4 on Stress Response of Nutrient-Starved Cardiovascular Cells
por: Mahmood, Abuzar, et al.
Publicado: (2015) -
Comparison of Cardiac miRNA Transcriptomes Induced by Diabetes and Rapamycin Treatment and Identification of a Rapamycin-Associated Cardiac MicroRNA Signature
por: Belenchia, Anthony M., et al.
Publicado: (2018)